Phase IIa trial of ICT 140 in patients with ovarian cancer at high risk of first recurrence

Trial Profile

Phase IIa trial of ICT 140 in patients with ovarian cancer at high risk of first recurrence

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs ICT 140 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2014 Planned number of patients changed from 60 to 56, as reported in an ImmunoCellular Therapeutics media release.
    • 13 Jan 2014 Enrolment is expected to begin in the third quarter of 2014, according to an ImmunoCellular Therapeutics media release.
    • 08 Aug 2013 Protocol was enhanced to include a larger patient population and a comparator group, according to an ImmunoCellular Therapeutics media release; the study will be at approximately 4 clinical sites.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top